Literature DB >> 27309631

Target Delivery of a Novel Antitumor Organoplatinum(IV)-Substituted Polyoxometalate Complex for Safer and More Effective Colorectal Cancer Therapy In Vivo.

Tiedong Sun1,2, Wei Cui2, Mei Yan1, Geng Qin2, Wei Guo1,2, Hongxi Gu1,2, Shaoqin Liu3, Qiong Wu4.   

Abstract

An inactive organoplatinum(IV)-substituted polyoxometalate is developed as an efficient and nontoxic prodrug with significant potential for treating human colorectal cancers. Further encapsulation of Pt(IV) -PW11 with DSPE-PEG2000 nanoparticles (NPs) enables targeted delivery and controlled release of inactive prodrug. Such Pt(IV) -PW11 -DSPE-PEG2000 NPs are highly efficient in inhibiting cellular growth of HT29 cells and treating human colorectal cancer in mice, superior to classic cisplatin.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antitumor activity; micelles; polyoxometalates; target delivery

Mesh：

Substances：

Year:  2016        PMID： 27309631     DOI： 10.1002/adma.201601778

Source DB:  PubMed          Journal:  Adv Mater        ISSN： 0935-9648            Impact factor:   30.849


  10 in total

1.  Anticancer Activity of Polyoxometalate-Bisphosphonate Complexes: Synthesis, Characterization, In Vitro and In Vivo Results.

Authors:  Amandine Boulmier; Xinxin Feng; Olivier Oms; Pierre Mialane; Eric Rivière; Christopher J Shin; Jiaqi Yao; Tadahiko Kubo; Taisuke Furuta; Eric Oldfield; Anne Dolbecq
Journal:  Inorg Chem       Date:  2017-06-20       Impact factor: 5.165

2.  Controlled drug delivery and cell adhesion for bone tissue regeneration by Keplerate polyoxometalate (Mo132)/metronidazole/PMMA scaffolds.

Authors:  Hamid Taghiyar; Bahram Yadollahi; Abolghasem Abbasi Kajani
Journal:  Sci Rep       Date:  2022-08-24       Impact factor: 4.996

3.  Genotoxicity and acute and subchronic toxicity studies of a bioactive polyoxometalate in Wistar rats.

Authors:  Xiaofeng Qu; Kun Xu; Chao Zhao; Xiuling Song; Jinhua Li; Li Li; Wei Nie; Hao Bao; Juan Wang; Fenglan Niu; Juan Li
Journal:  BMC Pharmacol Toxicol       Date:  2017-04-05       Impact factor: 2.483

4.  The Aquaporin-3-Inhibiting Potential of Polyoxotungstates.

Authors:  Catarina Pimpão; Inês V da Silva; Andreia F Mósca; Jacinta O Pinho; Maria Manuela Gaspar; Nadiia I Gumerova; Annette Rompel; Manuel Aureliano; Graça Soveral
Journal:  Int J Mol Sci       Date:  2020-04-02       Impact factor: 5.923

5.  Decavanadate Inhibits Mycobacterial Growth More Potently Than Other Oxovanadates.

Authors:  Nuttaporn Samart; Zeyad Arhouma; Santosh Kumar; Heide A Murakami; Dean C Crick; Debbie C Crans
Journal:  Front Chem       Date:  2018-11-20       Impact factor: 5.221

6.  Synthesis, Anti-Tumor Activity and Apoptosis-Inducing Effect of Novel Dimeric Keggin-Type Phosphotungstate.

Authors:  Yingxue Xue; Yifei Yin; He Li; Mingyu Chi; Jiaxin Guo; Guihua Cui; Wenliang Li
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

7.  Improving anti-cancer drug delivery performance of magnetic mesoporous silica nanocarriers for more efficient colorectal cancer therapy.

Authors:  Sonia Iranpour; Ahmad Reza Bahrami; Sirous Nekooei; Amir Sh Saljooghi; Maryam M Matin
Journal:  J Nanobiotechnology       Date:  2021-10-12       Impact factor: 10.435

Review 8.  Polyoxometalates as chemically and structurally versatile components in self-assembled materials.

Authors:  Yanting Gao; Manjiri Choudhari; Georgina K Such; Chris Ritchie
Journal:  Chem Sci       Date:  2021-12-22       Impact factor: 9.825

Review 9.  Promising application of polyoxometalates in the treatment of cancer, infectious diseases and Alzheimer's disease.

Authors:  Xuechen Wang; Shengnan Wei; Chao Zhao; Xin Li; Jin Jin; Xuening Shi; Zhenyue Su; Juan Li; Juan Wang
Journal:  J Biol Inorg Chem       Date:  2022-06-17       Impact factor: 3.862

Review 10.  Polyoxometalates as Potential Next-Generation Metallodrugs in the Combat Against Cancer.

Authors:  Aleksandar Bijelic; Manuel Aureliano; Annette Rompel
Journal:  Angew Chem Int Ed Engl       Date:  2018-10-12       Impact factor: 15.336
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.